|
Published today, the EU Pharmaceutical Strategy contains a number of proposals that can help Europe stem the 25-year trend of cutting-edge science and investment leaving Europe for the US and China. But choosing the right policy option to address the right issue will be critical to prevent further loss of competitiveness as the EU endeavours to regain its position as a world leader in medical innovation.
We welcome the recognition in the EU Pharmaceutical Strategy of the critical importance of incentives in driving research into areas of unmet medical need. Learning the lessons from the COVID-19 crisis, the inclusion in the Strategy of a series of measures to tackle antimicrobial resistance, (...)
Read more
|
